Abstract
Copyright © 2012 Charles Lin, Edward Sia and Jacqui Keller. This is an open access article distributed under the Creative Commons Attribution License unported 3.0, which permits unrestricted use, distribution, and reproduction in any medium, provided that original work is properly cited. Contact author: Charles Lin E-mail: Charles_Lin@health.qld.gov.au Concurrent Chemoradiation for T3 Glottic Squamous Cell Carcinoma: A Reasonable Alternative to Upfront Laryngectomy
Highlights
Upfront treatment options for stage III and IV larynx Squamous Cell Carcinoma (SCC) include laryngectomy or chemoradiation (CRT)
This study examined the rate of organ preservation and associated late morbidity for T3N+/-M0 glottic SCC treated with upfront concurrent CRT
Definitive concurrent CRT is a reasonable alternative to upfront laryngectomy for patients with T3N+/-M0 glottic carcinoma without significant morbidities
Summary
Upfront treatment options for stage III and IV larynx Squamous Cell Carcinoma (SCC) include laryngectomy or chemoradiation (CRT). The functional consequence of laryngectomy is debilitating (instant loss of voice in most cases) and significantly affects patients’ quality of life. This study examined the rate of organ preservation and associated late morbidity for T3N+/-M0 glottic SCC treated with upfront concurrent CRT
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.